AtriCure, Inc. , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced ...

Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Not all strokes are equally devastating, and new research shows that certain health risks don’t just increase your chances of ...

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

Researchers sought to determine the relationship among hospitalization for COPD exacerbation, AF burden, and risk for subsequent stroke.

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

(HealthDay News) — Average and brisk walking pace are associated with a decreased risk for cardiac arrhythmias, according to a study published online April 15 in Heart.

Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

Abbott (ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...